Plant Medicine Week Malta

MindBio Co-founder Justin Hanka delivers keynote address at Plant Medicine Week

#LSD #mentalhealth #microdosing

Recently, MindBio Therapeutics co-founder Justin Hanka gave a presentation at Plant Medicine Week in Malta. Justin spoke about the challenges of microdosing LSD, as well as how MindBio Therapeutics uses a combination of clinical trial data, Machine Learning, and AI to create an optimal microdosing regimen.

This is his presentation.

---

MindBio Therapeutics is a clinical-stage drug development company that is pioneering psychedelic microdosing. With its first candidate drug LSD currently in Phase 1 clinical trials microdosing LSD in 80 healthy participants.

In a world-first clinical trial of its kind, participants are prescribed the microdoses to take home with them after receiving a battery of psychological and biometric baseline tests in the laboratory. Phase 2 clinical trials microdosing LSD have just been approved in late-stage cancer patients experiencing existential distress, anxiety and depression.

MindBio Therapeutics has a unique drug formulation strategy that will integrate with artificial intelligence and technology development for the enhanced safety, optimal dosing and monitoring of patients.

#mentalhealth #microdosing #mindbio #AlbertHofmann #LSD #plantweek #plantmedicineweek